# EDGAR Filing Document

**Accession Number:** 0000749647
**File Stem:** 0001493152-25-022140
**Filing Date:** 2025-11
**Character Count:** 21737
**Document Hash:** f266fb2ae6b3bb13ed3e9e74c0384b1d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-022140.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001493152-25-022140

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**EFFECTIVENESS DATE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Imunon, Inc.
- **CENTRAL INDEX KEY:** 0000749647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521256615
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291493
- **FILM NUMBER:** 251475744

**BUSINESS ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648
- **BUSINESS PHONE:** (609) 896-9100

**MAIL ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsion CORP
- **DATE OF NAME CHANGE:** 20071121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CELSION CORP
- **DATE OF NAME CHANGE:** 19980515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEUNG LABORATORIES INC
- **DATE OF NAME CHANGE:** 19920703

**As filed with the Securities and Exchange Commission on November 13, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**IMUNON, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **52-1256615** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**997 Lenox Drive, Suite 100**

**Lawrenceville, NJ 08648-2311**

**(Address of principal executive offices) (Zip code)**

**Imunon, Inc. 2018 Stock Incentive Plan**

**(Full title of the plan)**

**Stacy R. Lindborg**

**President and Chief Executive Officer**

**997 Lenox Drive, Suite 100**

**Lawrenceville, NJ 08648**

**(609) 896-9100**

**(Name, address and telephone number, including area code, of agent for service)**

***Copies to:***

**Jurgita Ashley**

**Thompson Hine LLP**

**3900 Key Center**

**127 Public Square**

**Cleveland, Ohio 44114**

**(216) 566-5500**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

On July 11, 2025, the shareholders of Imunon, Inc. (the "Registrant") approved an amendment to the Imunon, Inc. 2018 Stock Incentive Plan, as amended as of July 11, 2025 (the "Amended Plan") to increase the number of shares of the Registrant's common stock, par value $0.01 (the "Common Stock") that are available for issuance thereunder by 133,333 shares. This Registration Statement on Form S-8 is being filed by the Registrant for the purpose of registering an additional 133,333 shares of Common Stock, in accordance with the Amended Plan. Pursuant to Instruction E of Form S-8, the contents of the (i) the Form S-8 Registration Statement ([File No. 333-273923](https://www.sec.gov/Archives/edgar/data/749647/000149315223027823/forms-8.htm)) filed with the Securities and Exchange Commission (the "Commission") on August 11, 2023, (ii) the Form S-8 Registration Statement ([File No. 333-266882](https://www.sec.gov/Archives/edgar/data/749647/000149315222023028/forms-8.htm)) filed with the Commission on August 15, 2022, (iii) the Form S-8 Registration Statement ([File No. 333-240275](https://www.sec.gov/Archives/edgar/data/749647/000149315220014364/forms-8.htm)) filed with the Commission on July 31, 2020, (iv) the Form S-8 Registration Statement ([File No. 333-233344](https://www.sec.gov/Archives/edgar/data/749647/000149315219012868/forms-8.htm)) filed with the Commission on August 16, 2019, and (v) the Form S-8 Registration Statement ([File No. 333-225045](https://www.sec.gov/Archives/edgar/data/749647/000143774918010365/clsn20180518_s8.htm)) filed with the Commission on May 18, 2018 are incorporated by reference herein, except to the extent supplemented, amended or superseded by the information set forth below.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:

1) The Registrant's [Annual Report on Form 10-K](https://www.sec.gov/Archives/edgar/data/749647/000149315225008460/form10-k.htm) for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025;

2) The Registrant's [Quarterly Report on Form 10-Q](https://www.sec.gov/Archives/edgar/data/749647/000164117225009572/form10-q.htm) for the fiscal quarter ended March 31, 2025, filed with the Commission on May 12, 2025;

3) The Registrant's [Quarterly Report on Form 10-Q](https://www.sec.gov/Archives/edgar/data/749647/000149315225011598/form10-q.htm) for the fiscal quarter ended June 30, 2025, filed with the Commission on August 5, 2025;

4) The Registrant's [Quarterly Report on Form 10-Q](https://www.sec.gov/Archives/edgar/data/749647/000149315225022120/form10-q.htm) for the fiscal quarter ended September 30, 2025, filed with the Commission on November 13, 2025;

5) The Registrant's Current Reports on Form 8-K filed with the Commission on [February 10, 2025](https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/form8-k.htm), [March 24, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225000207/form8-k.htm), [May 13, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225009775/form8-k.htm), [May 20, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225011601/form8-k.htm), [May 22, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225011999/form8-k.htm), [May 27, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225012395/form8-k.htm), [May 30, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225013051/form8-k.htm), [June 9, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225014279/form8-k.htm), [June 13, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225015124/form8-k.htm), [July 11, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225018797/form8-k.htm), [July 14, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225019541/form8-k.htm), [July 22, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225020520/form8-k.htm), [July 23, 2025](https://www.sec.gov/Archives/edgar/data/749647/000164117225020652/form8-k.htm), [July 28, 2025](https://www.sec.gov/Archives/edgar/data/749647/000149315225011440/form8-k.htm) and [August 28, 2025](https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/form8-k.htm), excluding any information furnished in such reports under Item 2.02, Item 7.01 or Item 9.01; and

6) Description of Securities of the Registrant, incorporated herein by reference to [Exhibit 4.7](https://www.sec.gov/Archives/edgar/data/749647/000149315225008460/ex4-7.htm) to the Annual Report on Form 10-K of the Registrant for the fiscal year ended December 31, 2024.

All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as "Incorporated Documents"). Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, or other information that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| 4.1 | [Restated Certificate of Incorporation, dated March 22, 2023, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on March 24, 2023.](https://www.sec.gov/Archives/edgar/data/749647/000149315223008888/ex3-1.htm) |
| 4.2 | [Amendment to the Restated Certificate of Incorporation, dated July 11, 2025, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on July 11, 2025.](https://www.sec.gov/Archives/edgar/data/749647/000164117225018797/ex3-1.htm) |
| 4.3 | [Amendment to the Restated Certificate of Incorporation, dated July 21, 2025, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on July 23, 2025.](https://www.sec.gov/Archives/edgar/data/749647/000164117225020652/ex3-1.htm) |
| 4.4 | [Amended and Restated Bylaws, effective on March 15, 2024, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on March 18, 2024.](https://www.sec.gov/Archives/edgar/data/749647/000149315224010195/ex3-1.htm) |
| 5.1\* | [Opinion of Thompson Hine LLP.](ex5-1.htm) |
| 23.1\* | [Consent of WithumSmith+Brown, PC.](ex23-1.htm) |
| 23.2\* | [Consent of Thompson Hine LLP (included in Exhibit 5.1).](ex5-1.htm) |
| 24.1\* | [Power of Attorney (set forth on the signature page of this Registration Statement).](#ja_001) |
| 99.1 | [Imunon, Inc. 2018 Stock Incentive Plan, as amended as of July 11, 2025, incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on July 14, 2025.](https://www.sec.gov/Archives/edgar/data/749647/000164117225019541/ex10-1.htm) |
| 99.2 | [Form of Incentive Stock Option Grant Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Registrant for the quarter ended March 31, 2024.](https://www.sec.gov/Archives/edgar/data/749647/000149315224018795/ex10-1.htm) |
| 99.3 | [Form of Restricted Stock Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Registrant for the quarter ended March 31, 2024.](https://www.sec.gov/Archives/edgar/data/749647/000149315224018795/ex10-2.htm) |
| 107\* | [Filing Fee Table.](ex107.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lawrenceville, State of New Jersey on November 13, 2025.

---

| | |
|:---|:---|
| **IMUNON, INC.** | **IMUNON, INC.** |
| By | */s/ Stacy R. Lindborg* |
|  | Stacy R. Lindborg, Ph.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Stacy R. Lindborg and Susan Eylward, acting alone or together with another attorney-in-fact, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, and any subsequent registration statements pursuant to Rule 462 of the Securities Act, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Stacy R. Lindborg* | President, Chief Executive Officer and Director | November 13, 2025 |
| Stacy R. Lindborg, Ph.D. | (Principal Executive Officer) |  |
| */s/ Kimberly Graper* | Chief Financial Officer | November 13, 2025 |
| Kimberly Graper | (Principal Financial and Accounting Officer) |  |
| */s/ Michael H. Tardugno* | Executive Chairman of the Board of Directors | November 13, 2025 |
| Michael H. Tardugno |  |  |
| */s/ Donald Braun* | Director | November 13, 2025 |
| Donald Braun, Ph.D. |  |  |
| */s/ James E. Dentzer* | Director | November 13, 2025 |
| James E. Dentzer |  |  |
| */s/ Frederick J. Fritz* | Director | November 13, 2025 |
| Frederick J. Fritz |  |  |
| */s/ Christine A. Pellizzari* | Director | November 13, 2025 |
| Christine A. Pellizzari |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

November 13, 2025

Imunon, Inc.

997 Lenox Drive, Suite 100

Lawrenceville, New Jersey 08648

Re: Registration Statement on Form S-8 – Imunon, Inc. 2018 Stock Incentive Plan, as amended as of July 11, 2025

Ladies and Gentlemen:

Imunon, Inc., a Delaware corporation (the "<u>Company</u>"), is filing with the Securities and Exchange Commission (the "<u>Commission</u>") a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to the issuance of up to 133,333 shares of common stock, par value $0.01 per share, of the Company (the "<u>Common Stock</u>"), issuable pursuant to the Company's 2018 Stock Incentive Plan, as amended as of July 11, 2025 (the "<u>Plan</u>"), as well as the authorized forms of stock option, restricted stock or other applicable award agreements under the Plan (collectively, the "<u>Award Agreements</u>").

Item 601 of Regulation S-K and the instructions to Form S-8 require that an opinion of counsel concerning the legality of the securities to be registered be filed as an exhibit to a Form S-8 registration statement if the securities are original issue shares. This opinion is provided in satisfaction of that requirement as it relates to the Registration Statement.

In rendering this opinion, we have examined copies of (a) the Company's Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws, each in the form filed as exhibits with the Commission, (b) the Plan, in the form filed as an exhibit with the Commission, and (c) such other records and documents as we have deemed advisable in order to render this opinion. In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, and the conformity to the originals or certified copies of all documents submitted to us as copies thereof.

As a result of the foregoing, and subject to the further limitations, qualifications and assumptions set forth herein, we are of the opinion that, under the laws of the State of Delaware, when issued pursuant to and in accordance with the Plan and the applicable Award Agreements, the shares of Common Stock that are the subject of the Registration Statement will be validly issued, fully paid, and non-assessable.

In rendering this opinion, we have assumed that the resolutions authorizing the Company to issue the shares of Common Stock pursuant to the Plan and the applicable Award Agreements will be in full force and effect at all times at which the shares of Common Stock are issued by the Company and that the Company will take no action inconsistent with such resolutions. We have further assumed that each award under the Plan will be approved by the Board of Directors of the Company or an authorized committee of the Board of Directors in accordance with applicable law.

Our opinion expressed above is limited to the General Corporation Laws of the State of Delaware, as currently in effect, and we express no opinion as to the effect on the matters covered by this letter of the laws of any other jurisdiction.

This opinion letter speaks only as of the date hereof. We expressly disclaim any responsibility to advise you of any development or circumstance of any kind, including any change of law or fact, that may occur after the date of this opinion letter that might affect the opinions expressed herein.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

---

| |
|:---|
| Very truly yours, |
| */s/ Thompson Hine LLP* |
| Thompson Hine LLP |

---

## Exhibit 23.1

**E** **xhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated February 26, 2025 (which includes explanatory paragraphs relating to the Company's ability to continue as a going concern), relating to the consolidated financial statements of Imunon, Inc. as of December 31, 2024 and 2023 appearing in the entity's Annual Report on Form 10-K for the year ended December 31, 2024.

---

| |
|:---|
| /s/ WithumSmith+Brown, PC |
| East Brunswick, New Jersey |
| November 12, 2025 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Table**

**Form S-8**

(Form Type)

**Imunon, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

Fees Previously Paid

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Amount Registered<sup>(</sup>**<sup>1**)**</sup>** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common stock, par value $0.01 per share Other<sup>(3)</sup>133333<sup>(2)</sup>$3.97<sup>(3)</sup> |  | $529332.01 | 0.00013810 | $73.10 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | $529332.01 |  | $73.10 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  | N/A |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  | $73.10 |

---

(1) Pursuant
 to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form
 S-8 (the "Registration Statement") also covers (i) such additional number of shares of common stock, par value $0.01
 per share, of Imunon, Inc. ("Common Stock") issuable upon stock splits, stock dividends, reclassifications, recapitalizations,
 combinations or similar events or (ii) such reduced number of shares of Common Stock in respect of any reverse stock splits, stock
 dividends, reclassifications, recapitalizations, combinations or similar events, in each case with respect to the shares of Common
 Stock being registered pursuant to this Registration Statement.

(2) Represents
 shares of Common Stock reserved for issuance under the Imunon, Inc. 2018 Stock Incentive Plan.

(3) Estimated
 in accordance with Rules 457(c) and 457(h) under the Securities Act solely for purposes of calculating the registration fee and based
 on the average of the high and low sales price per share of Common Stock as reported on The Nasdaq Stock Market LLC on November 7,
 2025, which date is within five business days prior to filing this Registration Statement.